Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.2.0.727
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 10,569 $ 8,391
Marketable securities, current 56,450 50,209
Collaboration receivable 3,647 7,248
Prepaid expenses and other current assets 1,500 832
Total current assets 72,166 66,680
Property and equipment, net 424 557
Other assets 1,264 1,159
Total assets 73,854 68,396
Current liabilities:    
Accounts payable 635 2,074
Accrued clinical and development expenses 7,720 5,998
Accrued liabilities 2,451 3,180
Deferred revenue, current 14,722 14,722
Total current liabilities 25,528 25,974
Warrant liability 19,627 3,961
Deferred revenue, non-current 54,833 62,194
Deferred rent 169 243
Total liabilities $ 100,157 $ 92,372
Commitments and contingencies (Note 7)    
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding    
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 71,334,779 shares at June 30, 2015 and 62,898,233 shares at December 31, 2014 $ 71 $ 63
Additional paid-in capital 366,366 349,236
Accumulated other comprehensive gain (loss) (18) (13)
Accumulated deficit (392,722) (373,262)
Total stockholders’ equity (deficit) (26,303) (23,976)
Total liabilities and stockholders’ equity (deficit) $ 73,854 $ 68,396